Dr. Christopher Barbieri was interviewed as a co-senior author on new prostate cancer research from Weill Cornell Medicine & colleagues, regarding the interpretation of PSA levels in patients with the SPOP prostate cancer subtype.
"These findings are counterintuitive," said co-senior author Dr. Christopher Barbieri, an assistant professor of urology at Weill Cornell Medicine. "In general, if your PSA is higher, the cancer is more dangerous. However, this study found that tumors associated with a high PSA and SPOP mutations were less dangerous."
Read the full article here on WCM Newsroom: https://news.weill.cornell.edu/news/2018/07/despite-high-psa-level-prost...
The study was published in JCO Precision Oncology and can be viewed here: http://ascopubs.org/doi/10.1200/PO.18.00036
